These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 16532090)

  • 1. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
    Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
    Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
    Nicolini A; Ferrari P; Sagripanti A; Carpi A
    Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
    Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
    Yildiz M; Oral B; Bozkurt M; Cobaner A
    Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
    del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
    Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
    Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
    Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
    Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
    J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
    Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
    Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
    Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
    Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
    Nicolini A; Carpi A; Ferrari P; Pieri L
    Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
    Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.